从国家“六五”期间起，北京大学肝病研究所一直承担着多项国家重点科技攻关项目。“十一五”期间承担6项国家重点科技攻关项目，“十二五”期间承担7项国家重点科技攻关项目，“十三五”期间承担7项国家重点科技攻关项目。并逐步形成3个主要研究方向，（1）慢性乙型肝炎和丙型肝炎的研究；（2）脂肪肝：流行病学，诊断和机制研究；（3）肝癌：肝癌发生发展、转移复发的机制和肝癌免疫治疗的研究

 

       北京大学肝病研究所现有职工91人，其中高级职称17人。床位48张，年门诊量7万6千余人次，年住院900余人次。肝病研究所与全球同行有广泛的学术交流和合作，近年与美国密歇根大学，新加坡科技局的同行展开多项合作研究。建所以来研发了我国第一支乙肝疫苗，第一批乙型肝炎和丙型肝炎的免疫学及分子生物学诊断试剂，为病毒性肝炎的防治做出了历史性贡献。我所已获国家科技进步一等奖1项，二等奖3项，三等奖1项，其它省部级奖项80余次。

 

       新型冠状病毒疫情期间，北京大学肝病研究所是北京市第一批新型冠状病毒核酸检测实验室，并获得确证实验室资质，为抗击疫情争取了宝贵的时间，并进行了真实世界中注射新冠疫苗后抗体水平的研究。对我国慢性丙型肝炎病毒感染者队列进行了随访和治疗方案优化研究，建立了疗效评价体系难治性丙型肝炎通过优化方案的治疗。建立了一项新型用于全面和定量评估脂肪肝患者组织学特征的方法qFIBS，为脂肪肝药物研发提供了客观的工具。鉴定了多个肝细胞癌的驱动基因并阐明了其分子机制。结合全基因组CRISPR筛选系统，在肝细胞癌中发现了多个调控免疫检查点PD-L1和CD155表达的关键基因，为肝癌的抗肿瘤免疫治疗提供了新靶点；建立了肝癌特异性抗原预测和筛选平台，获得中国人群特异性的高免疫原性抗原表位库，为新生抗原个体化疫苗的临床试验开展奠定基础；结合公共数据库和自有肝癌队列，建立了多个肝癌预后的预测模型。在这些研究中共发表了SCI论文100余篇，获得国内专利10项，申报国际专利1项。

 

机构负责人：饶慧瑛

联系人：饶慧瑛

邮箱：rao.huiying@163.com

电话：010-88325723

地址：北京市西城区西直门南大街11号

网址链接：https://www.pkuph.edu.cn/beida_department.html

 

Peking University Hepatology Institute

Peking University Hepatology Institute (PUHI), the first institute for viral hepatitis in China, was established in 1978，grew out of Being Medical School People’s Hospital Hepatology Institute and, through 40 years of development, have grew to become a comprehensive institute, including Research Institute, Department of Hepatology, Department of Infectious Disease, Clinical Lab and Post-Doctoral Research Center of Peking University. For our pioneering work in the treatment and study of liver and infectious diseases, PUHI was awarded the Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, a Clinical Pharmacology Research centers by the Ministry of Health and SFDA of PRC, and a National Key Clinical Specialty of Infectious Disease. For the commitment in clinical laboratory ever since its establishment, the Clinical Lab of PUHI passed the Laboratory Accreditation Programme held by CAP (College of American Pathologists) and CNAS (China National Accreditation Service for Conformity Assessment), and participated in the China’s national laboratory network for infectious disease. In 2020, PUHI became one of the first medical institutions to carry out SARS-CoV-2 viral nucleic acid detection in Beijing. It was supported by the National Major Disease Multidisciplinary Cooperation Capacity Building Project, and was supported by the Beijing key clinical specialist program (Infectious Disease Branch).

PUHI led or undertake a large number of National Key S & T Projects since the "6th Five-Year Plan" of China, and participate in up to six, seven and seven projects during the “11th to 13th Five-Year Plan”, respectively. PUHI is committed to advancing research in areas including: (1) Hepatitis B and Hepatitis C (2) Fatty liver- epidemiology, diagnosis and mechanism study y; (3) Hepatocellular carcinoma: the mechanism of HCC pathogenesis, metastasis and recurrence, immunotherapy of HCC.

PUHI have 91 doctors, nurses and researchers, and 17 are senior professional titles. There were 48 beds and more than seventy thousand people in the annual outpatient department, and more than 900 people were hospitalized in the year. PUHI have also established international collaborations with colleagues around the world, including University of Michigan (United States), and Agency for Science, Technology and Research (A*STAR, Singapore).

PUHI have made historic contributions to the prevention and treatment of viral hepatitis in China by developing the first HBV vaccine and first generation of HBV and HCV diagnostic agent. PUHI have received more than eighty awards, including one 1st prize, three 2nd prizes and one 3rd Prize National Science and Technology Progress Award from the Ministry of Science and Technology.

During the COVID-19 pandemic, PUHI was certified laboratory qualification of SARS-CoV-2 viral nucleic acid detection and has gained valuable time for fighting against the epidemic situation. PUHI also carried out a study on the antibody level in the real world after the injection of COVID-19 vaccine. A follow-up and treatment plan optimization study were carried out on the cohort of patients with chronic hepatitis C virus infection in China, and a curative effect evaluation system was established. Refractory hepatitis C was treated by optimizing the plan. A new method qFIBS (Quantitative fibrosis, inflammation, Balloning, steatosis) was established to comprehensively and quantitatively evaluate the histological characteristics of patients with fatty liver, which provides an objective tool for the research and development of fatty liver drugs. Several driving genes of hepatocellular carcinoma were identified and their molecular mechanisms were clarified. Combined with the whole genome CRISPR screening system, several key genes regulating the expression of immune checkpoints PD-L1 and CD155 were found in hepatocellular carcinoma, which provides several new targets for antitumor immunotherapy of hepatocellular carcinoma; The platform for predicting and screening liver cancer specific antigen was established, and the high immunogenic antigen epitope library specific to Chinese population was obtained, which laid a foundation for the clinical trial of newborn antigen individualized vaccine; Combined with the public database and our own liver cancer cohort, several prediction models of liver cancer prognosis were established. In these studies, more than 100 SCI papers have been published and 10 domestic patents have been obtained and 1 international patent are declared.

 

Director of the agency: Hui-Ying Rao

Contact: Hui-Ying Rao

E-mail: rao.huiying@163.com

Tel: 010-88325723

Address: Xizhimen South Street No.11

Website: https://www.pkuph.edu.cn/beida_department.html